The critical role of biomedical research in pandemic preparedness

JAMA - Journal of the American Medical Association

Volumn 318, Issue 18, 2017, Pages 1757-1758

  Marston, Hilary D ^a   Paules, Catharine I ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

DISEASE SURVEILLANCE; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL MANAGEMENT; HEALTH HAZARD; HOMOSEXUAL MALE; HUMAN; KAPOSI SARCOMA; LIFE THREAT; MEDICAL RESEARCH; NONHUMAN; PANDEMIC; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH CAMPAIGN; SARS CORONAVIRUS; SHORT SURVEY; ZIKA VIRUS; COMMUNICABLE DISEASE CONTROL; HEALTH CARE PLANNING;

BIOMEDICAL RESEARCH; COMMUNICABLE DISEASE CONTROL; HEALTH PLANNING; HUMANS; PANDEMICS;

EID: 85034656539     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.15033     Document Type: Short Survey

References (7)

1. World Health Organization. International Health Regulations (2005). 3rd ed. http://apps.who.int/iris/bitstream/10665/246107/1/9789241580496-eng .pdf?ua=1. Accessed August 23, 2017.
2. Global Health Security Agenda. Advancing the Global Health Security Agenda: Progress and Early Impact From U.S. Investment. 2016. https://www.ghsagenda.org/docs/default-source/default-document-library/ghsa-legacy-report.pdf ?sfvrsn=12. Accessed August 23, 2017.
3. Sapparapu G, Fernandez E, Kose N, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016; 540(7633):443-447.
4. Dhillon RS, Srikrishna D, Garry RF, Chowell G. Ebola control: rapid diagnostic testing. Lancet Infect Dis. 2015;15(2):147-148.
5. World Health Organization. Methodology for Prioritizing Severe Emerging Diseases for Research and Development. February 2017. http://www.who.int/blueprint/priority-diseases/RDBlueprint -PrioritizationTool.pdf?ua=1. Accessed August 24, 2017.
6. Pavot V. Ebola virus vaccines: where do we stand? Clin Immunol. 2016;173:44-49.
7. Martin JE, Louder MK, Holman LA, et al; VRC 301 Study Team. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine. 2008;26(50):6338-6343.